{"entity":{"id":"panbela-therapeutics","kind":"company","name":"Panbela Therapeutics","aka":["Sun BioPharma","NASDAQ:PBLA"],"tldr":"Panbela Therapeutics is a Minnesota biotech whose drug ivospemin starves pancreatic cancer of polyamines, molecules the tumour needs to grow, and is being tested with gemcitabine and nab-paclitaxel in first-line treatment.","summary":"Panbela Therapeutics, formerly Sun BioPharma, develops polyamine-targeting therapies. Ivospemin (SBP-101) is a polyamine analogue that is taken up preferentially by pancreatic acinar and cancer cells and disrupts polyamine metabolism. The phase 2/3 ASPIRE trial tested ivospemin with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma. Through its acquisition of Cancer Prevention Pharmaceuticals it also holds eflornithine-based programmes for familial adenomatous polyposis.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.panbela.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["ivospemin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Waconia, Minnesota","country":"US","companyType":"biotech","website":"https://www.panbela.com/","ticker":"NASDAQ:PBLA","stage":"public","investors":[],"funding":[]},"route":"/companies/panbela-therapeutics/","neighbours":{"drug":[{"id":"ivospemin","kind":"drug","name":"Ivospemin","route":"/drugs/ivospemin/"}]}}